Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: Potential importance of pathway intermediates by Jonas, Abdel-Khalik et al.
Journal of Steroid Biochemistry and Molecular Biology 206 (2021) 105794
Available online 24 November 2020
0960-0760/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing 
cholesterol: Potential importance of pathway intermediates 
Jonas Abdel-Khalik a, Thomas Hearn a, Alison L. Dickson a, Peter J. Crick a, Eylan Yutuc a, 
Karl Austin-Muttitt a, Brian W. Bigger b, Andrew A. Morris c, Cedric H. Shackleton d, 
Peter T. Clayton e, Takashi Iida f, Ria Sircar g, Rajat Rohatgi g, Hanns-Ulrich Marschall h, 
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High-Performance liquid chromatography 
A B S T R A C T   
Bile acids are the end products of cholesterol metabolism secreted into bile. They are essential for the absorption 
of lipids and lipid soluble compounds from the intestine. Here we have identified a series of unusual Δ5-un-
saturated bile acids in plasma and urine of patients with Smith-Lemli-Opitz syndrome (SLOS), a defect in 
cholesterol biosynthesis resulting in elevated levels of 7-dehydrocholesterol (7-DHC), an immediate precursor of 
cholesterol. Using liquid chromatography – mass spectrometry (LC–MS) we have uncovered a pathway of bile 
acid biosynthesis in SLOS avoiding cholesterol starting with 7-DHC and proceeding through 7-oxo and 7β- 
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Mass spectrometry 
Hedgehog signalling pathway 
hydroxy intermediates. This pathway also occurs to a minor extent in healthy humans, but elevated levels of 
pathway intermediates could be responsible for some of the features SLOS. The pathway is also active in SLOS 
affected pregnancies as revealed by analysis of amniotic fluid. Importantly, intermediates in the pathway, 25-hy-
droxy-7-oxocholesterol, (25R)26-hydroxy-7-oxocholesterol, 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid and 
the analogous 7β-hydroxysterols are modulators of the activity of Smoothened (Smo), an oncoprotein that me-
diates Hedgehog (Hh) signalling across membranes during embryogenesis and in the regeneration of post-
embryonic tissue. Computational docking of the 7-oxo and 7β-hydroxy compounds to the extracellular cysteine 
rich domain of Smo reveals that they bind in the same groove as both 20S-hydroxycholesterol and cholesterol, 
known activators of the Hh pathway.   
1. Introduction 
Bile acids are a large family of steroids possessing an acidic group on 
the side-chain [1]. The family can be considered to include both C24 
acids containing the four-ring steroid skeleton with a 5-carbon 
side-chain and C27 acids with an 8-carbon side-chain attached to the 
steroid skeleton [2]. They are synthesised in the liver [3], but steps in 
their biosynthesis may also proceed extrahepatically [4], e.g. in brain 
[5]. Bile acids are synthesised predominantly via two pathways. The 
dominating pathway in human is the “neutral” or “normal” pathway 
which starts with 7α-hydroxylation of cholesterol by the hepatic cyto-
chrome P450 (CYP) 7A1 enzyme [3]. The second pathway, known as the 
“acidic” pathway, starts with (25R)26-hydroxylation of cholesterol by 
CYP27A1 to give (25R)26-hydroxycholesterol (26− HC) either in the 
liver or extrahepatically [3,4,6,7]. Note, we use the systematic 
numbering system to describe (25R)26-hydroxylation of cholesterol 
according to IUPAC rules, however, much of the literature describes the 
resulting product as 27-hydroxycholesterol (27− HC) [8]. Unless stated 
otherwise (25R) stereochemistry is generally assumed. See Supple-
mental Tables for lists of common and systematic names of compounds 
analysed in this work. Other minor pathways begin with 25-hydroxyl-
ation of cholesterol by cholesterol 25-hydroxylase (CH25H) [3,4,9] in 
e.g. activated macrophages [10], or with 24S-hydroxylation of choles-
terol by cholesterol 24S-hydroxylase (CYP46A1) in brain [3]. Many of 
the subsequent enzymes converting hydroxycholesterols to bile acids are 
operative in multiple pathways allowing metabolite crossing between 
pathways [4,7]. 
The major bile acids in human are cholic, chenodeoxycholic, deox-
ycholic and lithocholic acids. The latter two are derived from the former 
two by 7α-dehydroxylation. Ursodeoxycholic is also present in human 
but rarely as a major bile acid [11]. Bile acids are secreted in bile as 
glycine or taurine conjugates, or in the case of lithocholic acid as a 3-sul-
fate. Bile acids function in the intestine to aid absorption of lipids and 
are recycled to the liver via the enterohepatic system. As well as func-
tioning as detergents in the intestine bile acids are also signalling mol-
ecules, regulating their own synthesis via interaction with the farnesoid 
X receptor (FXR, NR1H4) [12], while intermediates in their biosynthetic 
pathways from cholesterol are ligands to other nuclear receptors e.g. 
liver X receptors (LXRs, NR1H3, NR1H2) [13], pregnane X receptor 
(PXR, NR1I2) [14], vitamin D receptor (VDR, NR1I1) [15], constitutive 
androstane receptor (CAR, NR1I3) [16]; to G protein-coupled receptors 
(GPCRs) e.g. GPR183 also named EBI2 [17] and GPBAR1 also called 
TGR5 [18]; and are allosteric modulators of N-methyl-D-aspartate re-
ceptors (NMDARs) [19]. Interestingly, some steps in bile acid biosyn-
thesis may occur in the nervous system and almost all of the acidic 
pathway intermediates from cholesterol to bile acids can be found in 
brain or cerebrospinal fluid (CSF) [5,20], and many of these in-
termediates can cross the blood brain barrier providing traffic in and out 
of the central nervous system (CNS) [21,22]. Cholic acid has been 
identified in rodent brain [23] and shown to act as a ligand to LXRs 
regulating the neurogenesis of red nucleus neurons [24], while the C27 
bile acid 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid (3β,7α-diHCA) 
has been shown to regulate the survival of motor neurons, again through 
interaction with LXRs [25]. 
Unsurprisingly, deficiency in enzymes of the bile acid biosynthesis 
pathways lead to disease [26], however, as a consequence of the 
redundancy provided by multiple pathways, often not to a total elimi-
nation of bile acid formation e.g. in cerebrotendinous xanthomatosis 
(CTX) where even though there is a deficiency of CYP27A1 some cholic 
acid formation is maintained [27]. Likewise, defects in cholesterol 
biosynthesis result in clinical disorders [28], however, it is unknown if 
there is sufficient metabolic redundancy for cholesterol to be bypassed 
and bile acid biosynthesis maintained by alternative metabolic 
pathways. 
In the current work we propose how uncommon Δ5-unsaturated bile 
acids can be biosynthesised via an unusual pathway from 7-dehydrocho-
lesterol (7-DHC), an immediate precursor of cholesterol, in patients with 
the malformation disorder Smith-Lemli-Opitz syndrome (SLOS) where 
the enzyme 7-dehydrocholesterol reductase (DHCR7) is deficient and 7- 
DHC is abundant in tissues and plasma (Fig. 1). One branch of this 
pathway is also prevalent in SLOS-affected pregnancies as revealed here 
by analysis of amniotic fluid. We identify in human plasma the pathway 
intermediates 25-hydroxy-7-oxocholesterol (25H,7O-C), 7β,25-dihy-
droxycholesterol (7β,25-diHC), (25R)26-hydroxy-7-oxocholesterol 
(26H,7O-C), 7β,(25R)26-dihydroxycholesterol (7β,26-diHC), 3β-hy-
droxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA), 3β,7β-dihy-
droxycholest-5-en-(25R)26-oic acid (3β,7β-diHCA), 3β,7β,24- 
trihydroxycholest-5-en-26-oic acid (3β,7β,24-triHCA) and 3β,7β,25-tri-
hydroxycholest-5-en-26-oic acid (3β,7β,25-triHCA) and the unsaturated 
C24 bile acids 3β-hydroxy-7-oxochol-5-enoic (3βH,7O-Δ5-BA) and 3β,7β- 
dihydroxychol-5-enoic acids (3β,7β-diH-Δ5-BA). With the exception of 
3βH,7O-Δ5-BA, each of these metabolites was identified by liquid 
chromatography – mass spectrometry (LC–MS) with reference to 
authentic standards; 3βH,7O-Δ5-BA being identified by predicted accu-
rate mass, retention time and multistage fragmentation (MSn) spectra. 
We did not have authentic standards of 3β,7β,24-triHCA or 3β,7β,25- 
triHCA but we did have standards for the 7α-epimers, the retention time 
and MS3 spectra of which give confidence to the identification of the 7β- 
epimers. The 7-oxo metabolites and also the ultimate metabolite, 3β,7β- 
diH-Δ5-BA, were also found in amniotic fluid from SLOS affected preg-
nancies. The Δ5-unsaturated C24 bile acids have previously been iden-
tified as their respective sulfate and N-acetylglucosamine (GlcNAc) 
conjugates in serum and urine from patients with the lysosomal storage 
disease Niemann-Pick disease type C (NP-C), as have also a number of 
these pathway intermediates [29–32]. 
The biological significance of this unusual bile acid biosynthesis 
pathway found in SLOS and starting with 7-DHC is discussed in light of 
previous reports that pathway intermediates 25H,7O-C, 26H,7O-C and 
7β,26-diHC bind to and activate the extracellular cysteine rich domain 
(CRD) of the oncoprotein Smoothend (Smo, FZD11) [33,34], a GPCR 
involved in the Hedgehog (Hh) signalling pathway which during 
embryogenesis controls the development of many tissues and after 
development regulates tissue stem cells and regenerative response to 
injury [35,36]. We show that 7β,25-diHC and other pathway in-
termediates, 3βH,7O-CA and 3β,7β-diHCA, also binds to Smo and acti-
vates Hh signalling. Through computational molecular docking we show 
that the 7-oxo compounds, 25H,7O-C, 26H,7− OC and 3βH,7O-CA, and 
the analogous 7β-hydroxysterols, bind to the same oxysterol binding 
J. Abdel-Khalik et al.                                                                                                                                                                                                                           
Journal of Steroid Biochemistry and Molecular Biology 206 (2021) 105794
3
Fig. 1. Bile acid biosynthesis starting with 7-DHC and ending with GlcNAc conjugates of 3β,7β-diH-Δ5-BA. The metabolites of elevated abundance found in plasma 
from SLOS patients are indicated by an upward pointing blue arrow and those elevated in amniotic fluid from SLOS affected pregnancies by an upward pointing red 
arrow. Metabolites of elevated abundance found in SLOS urine are indicated by a green upwards pointing arrow. Oxysterols, including C24 and C27 acids, found in 
plasma are shown in blue, bile acid conjugates found in urine are in green. The enzyme(s) for each step is in black. There is also minor non-enzymatic formation of 
7− OC which may be more important in some lysosomal storage disorders [30]. Systematic and common names of molecular structures can be found in Supplemental 
Tables 1 & 2. For simplicity 3β,7β,24-triHCA is shown as the carboxylic acid rather than the CoA thioester. The 7-oxocholesterol 25-hydroxylase is not known, many 
CYP enzymes, and also CH25H, have sterol 25-hydroxylase activity. 
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groove in the CRD of Smo but show different patterns of hydrogen 
bonding. Importantly, abnormal Hh signalling has been implicated in 
human birth defects and many of the malformations found in SLOS are 
consistent with impaired Hh signalling [37]. 
2. Results 
2.1. Plasma analysis 
It has been shown that CYP7A1 can convert 7-DHC to 7-oxocholes-
terol (7− OC) [38] and it is known that 7− OC can be converted to 
7β-hydroxycholesterol (7β− HC) by hydroxysteroid dehydrogenase 
(HSD) 11B1 in human and rodent (Fig. 1) [39–41]. This suggests that 
patients suffering from SLOS may use 7-DHC as a starting point for bile 
acid biosynthesis in addition to cholesterol. We thus investigated using 
LC–MS exploiting charge-tagging and MSn (see Supplemental Figure S1) 
[30,42–44] the nature of bile acid intermediates found in plasma from 
patients suffering from SLOS. Previously, we were able to detect 
elevated levels of 7-DHC and its metabolites, 7− OC and 7β− HC (re-
ported in (44)), and here we report elevated concentrations of the 
down-stream acids 3β,7β-diHCA and 3β,7β-diH-Δ5-BA in SLOS plasma 
(Figs. 2 & 3 , Supplemental Table S1, Supplemental Figure S2). Note, we 
did not include a saponification step in our sample preparation protocol, 
so concentrations of C27 sterols refer to non-esterified molecules. This is 
justified as it is the non-esterified sterols that have been identified to be 
biologically active. In patient samples where the 7-DHC + 8-DHC to 
cholesterol ratio is high (7-DHC isomerises to 8-DHC (44)), 26H,7O-C, 
7β,26-diHC, 3βH,7O-CA and 3βH,7O-Δ5-BA acids were also observed 
(Figs. 1–4, Supplemental Table S1, Supplemental Figure S2). In the 
absence of an authentic standard the latter compound was identified 
based on exact mass, MSn spectra and retention time. Other compounds 
found to be elevated in SLOS samples where the 7-DHC + 8-DHC to 
cholesterol ratio is high were 25H,7O-C and 7β,25-diHC (Supplemental 
Table S1). Low levels of metabolites with retention time and MSn frag-
mentation patterns consistent with 3β,7β,24-triHCA and 3β,7β, 
25-triHCA structures were presumptively identified by comparison to 
the 7α-epimers which were available as authentic standards (Fig. 3, 
Supplemental Table S1, Supplemental Figure S2). These twelve metab-
olites fall on three branches of an unusual bile acid biosynthesis pathway 
starting from 7-DHC and proceeding to 3β,7β-diH-Δ5-BA (Fig. 1). 
As sterols with a 3β,7α-dihydroxy-5-ene structure are converted to 
analogous sterols with a 7α-hydroxy-3-oxo-4-ene structure in the neutral 
and acidic pathways of bile acid biosynthesis by the enzyme HSD3B7 
[3], we investigated whether similar reactions proceeded with 3β, 
7β-dihydroxy-5-ene substrates. We found no evidence of sterols with a 
7β-hydroxy-3-oxo-4-ene structure in our LC–MS analysis. 
Unfortunately, we did not measure absolute concentrations of 7- 
DHC, 8-DHC or of cholesterol, only the 7-DHC + 8-DHC to cholesterol 
ratio [44]. Neither, do we have access to extensive clinical data, so we 
have not attempt to correlate metabolite levels to disease severity. 
However, it should be noted that the samples showing the highest 
7-DHC + 8-DHC to cholesterol ratios also showed high concentration of 
pathway intermediates down-stream from 7− OC and 7β− HC, although 
not necessarily the highest concentrations per se. Looking in reverse, the 
SLOS plasma sample with the lowest 7-DHC + 8-DHC to cholesterol ratio 
in all cases showed the lowest levels of pathway intermediates beyond 
7− OC and 7β− HC. It is of interest that the outliers Figs. 3C, D and F, 
relating to concentrations of 3β,7β-diHCA, 3β,7β,24-triHCA and 3β, 
7β-diH-Δ5-BA, the three final metabolites in the pathway from 7β− HC to 
3β,7β-diH-Δ5-BA are all from the same sample. The level of 7β− HC in 
this sample was similar to the mean for the SLOS sample set, while levels 
of the 7-oxo metabolites in this sample were low. This data suggests high 
activity of HSD11B1 (reductase) compared to HSD11B2 (oxidase) in this 
patient. Further studies with well curated clinical information on a 
larger set of samples are planned. 
2.2. Amniotic fluid analysis 
Among other vital roles, amniotic fluid serves to facilitate the ex-
change of biochemicals between mother and foetus [45]. Previous 
studies have shown that SLOS affected-pregnancies can be diagnosed by 
MS analysis of this fluid through measuring elevated levels of 7-DHC and 
its isomer 8-DHC generated by the affected foetus [46,47]. As SLOS 
presents before birth it is possible that metabolites of the unusual 
pathway of bile acid biosynthesis may be present in amniotic fluid. As 
reported previously [47], we found an increase in the ratio of 7-DHC 
plus 8-DHC to cholesterol in SLOS affected-pregnancies. In addition, 
levels of 26H,7O-C, 3βH,7O-CA, 3βH,7O-Δ5-BA, 3β,7β,25-triHCA and 
3β,7β-diH-Δ5-BA were similarly elevated in SLOS amniotic fluid samples 
(Supplemental Table S1, Supplemental Figure S3). 
2.3. Urine analysis 
Sterols with a 3β,7β-dihydroxy-5-ene function have not been re-
ported to be substrates for HSD3B7 [48], the oxidoreductase normally 
required to initiate A/B ring transformation ultimately leading to the 
3α-hydroxy-5β-hydrogen configuration found in primary bile acids [3]. 
We failed to detect any 7β-hydroxy-3-oxo-4-ene sterols in our analysis of 
SLOS plasma, supporting the data of Furster et al. and the contention 
that HSD3B7 is inactive towards 3β,7β-dihydroxy-5-ene sterols, at least 
in human and pig [48]. We propose that the 3β,7β-dihydroxy-5-ene 
structure is maintained in the pathway intermediates from 7-DHC to bile 
acids as described by the central branch of the pathway in Fig. 1. Sterols 
possessing a 7β-hydroxy group are known to be conjugated with GlcNAc 
and excreted in urine [49], hence it might be expected that the urine of 
SLOS patients would contain elevated levels of unsaturated GlcNAc 
conjugated bile acids. Using LC–MS at high mass resolution with MSn, i. 
e. LC–MS(MSn), we determined the total bile acid content of urine by 
summing the amounts of mono-, di- and trihydroxycholanoic acids, their 
single and doubly unsaturated equivalents and single, double and triple 
conjugates with glycine or taurine, sulfuric acid and GlcNAc. We found 
significantly elevated levels of 3β,7β-diH-Δ5-BA conjugated with GlcNAc 
at position 7β in urine from SLOS patients and also the double conjugate 
with sulfuric acid (S) at C-3β (Fig. 5). Note, that we did not have 
authentic standards of the Δ5-unsaturated GlcNAc conjugates, but 
LC-retention times, exact mass measurements and MS2 spectra were 
consistent with 7β-GlcNAc conjugation. While we are confident that the 
sugar is an N-acetylhexosamine (HexNAc), based on accurate mass and 
MS2 spectra, we cannot be absolutely sure that it is GlcNAc (in the 
absence of GC–MS analysis of the monosaccharide), however, to the best 
of our knowledge no other HexNAc sugar has been found conjugated to a 
bile acid at C-7 [1,11,29,49]. Other double conjugates with GlcNAc 
(C-7β) and also glycine or taurine (C-24), and triple conjugates with 
glycine or taurine, sulfuric acid and GlcNAc were also found to be 
elevated significantly in SLOS urine (Figs. 1 & 5, Supplemental Table S2, 
Supplemental Figure S4). There was no overlap in the levels of the 3β, 
7β-diH-Δ5-BA GlcNAc conjugates in urine samples from the SLOS and 
control groups, although we did only analyse three SLOS samples and six 
control samples. We also found elevated levels of 3βH,7O-Δ5-BA con-
jugated with sulfuric acid in one of the patient samples analysed and 
increased levels of the double conjugate with sulfuric acid and glycine in 
two patient samples. 
2.4. Hedgehog signalling 
Hh signalling provides a cell – cell communication system across 
membranes in all animals. The receptor for the Hh-protein ligands, 
Patched 1 (Ptch1) inhibits signalling by supressing the activity of Smo 
(Fig. 6). Sonic hedgehog (SHH) protein binds to and inhibits Ptch1, 
allowing Smo to adopt an active conformation and transmit signal across 
the plasma membrane, ultimately leading to nuclear translocation of the 
Gli family of Hh transcription factors and activation of Hh target genes 
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Fig. 2. Concentration of 7-DHC and its metabolites in SLOS (n = 10 patients) and control (n = 24 volunteers) plasma samples. (A) Concentration of 7-DHC plus 8- 
DHC in ng/μg cholesterol. 8-DHC is an isomerisation product of 7-DHC. Concentrations of all other oxysterols are in ng/mL. (B) 7− OC. (C) 7β− HC. (D) 26H,7O-C. (E) 
7β,26-diHC. (F) 25H,7O-C. Concentrations determined by LC–MS(MSn) exploiting charge-tagging utilising the Girard P reagent (GP) [42]. See Supplemental 
Figure S2 for relevant chromatograms. The bottom and top of the box are the first and third quartiles, and the band inside the box represents the median. The 
whiskers extend to the most extreme data points which are no more than 1.5 times the range between first and third quartile distant from the box. Points beyond that 
are plotted individually. Mann-Whitney test was used for comparison of non-normally distributed data. *, P < 0.05; **, P < 0.01. Data for 7-DHC + 8-DHC, 7− OC 
and 7β− HC has been reported in [44]. 
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including Gli1 [36,50]. Recent studies have indicated that 25H,7O-C, 
26H,7O-C and 7β,26-diHC, can activate the Hh signalling pathway in 
the absence of SHH [33,34]. Thus, we performed a Hh signalling assays 
using quantitative RT-PCR to measure mRNA levels of Gli1, commonly 
used as a metric for Hh signalling strength, following stimulation (7.5 h) 
of NIH/3T3 cells with these three oxysterol and other oxysterols found 
to be elevated in SLOS plasma. As expected, 25H,7O-C, 26H,7O-C and 
7β,26-diHC induced Gli1 mRNA, as did other pathway metabolites 7β, 
Fig. 3. Concentration (ng/mL) of 7β-hydroxy and 7-oxo C24 and C27 acids in SLOS (n = 10) and control (n = 24) plasma. (A) 3βH,7O-CA. (B) 3βH,7O-Δ5-BA. (C) 
3β,7β-diHCA. (D) 3β,7β,24-triHCA. (E) 3β,7β,25-triHCA. (F) 3β,7β-diH-Δ5-BA. See Supplemental Figure S2 for relevant chromatograms. Concentrations determined 
and statistical comparisons were as described in the caption to Fig. 2. 
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25-diHC, 3βH,7O-CA and 3β,7β-diHCA (Fig. 4). For comparison incu-
bation of NIH/3T3 cells with 300 nM SHH gave about the same level of 
Gli1 mRNA as 10 μM 26H,7O-C. 
As SLOS is a developmental disorder, we decided to focus on the 7- 
oxo branch of the unusual pathway in Fig. 1 which involves metabo-
lites found to be elevated in amniotic fluid from SLOS affected preg-
nancies. To investigate if the 7-oxo compounds bind to Smo through its 
extracellular CRD we used the purified CRD from zebrafish Smo and 
tested it for binding to 20S-hydroxycholesterol (20S− HC) immobilised 
on beads [35] in the presence of the 7-oxo competitors. 20S− HC is 
known to bind to the CRD of vertebrate Smo and to activate Hh sig-
nalling [35,51]. In the absence of competitor (none) Smo robustly binds 
to 20S− HC beads (Fig. 4) [35,51]. In agreement with an earlier report, 
26H,7O-C and 25H,7O-C are very good competitors for Smo binding 
[33], similar to 20S− HC. We now find that 3βH,7O-CA also acts as a 
competitor for the binding of Smo CRD to 20S-beads (Fig. 4). These data 
provide support for the concept that the 7-oxo compounds can bind to 
the extracellular CRD of Smo and modulate Hh signalling during 
development. As SLOS is a disease which phenocopies deficient Hh 
signalling [37], dysregulation of the balance between SMO modulators 
Fig. 4. Identification of 7-oxo metabolites in SLOS plasma and amniotic fluid and demonstration that they modulated Hh signalling by binding to the CRD of 
vertebrate Smo. LC–MS3 chromatograms of GP-tagged 26H,7− OC (upper panel) and 3βH,7O-CA (lower panel) in SLOS (A) amniotic fluid; and (B) plasma. The 
identities of the sterols eluting after 26H,7− OC in the amniotic fluid sample and before 26H,7− OC in the plasma sample are unknown. SLOS samples are known to be 
rich in multiple sterols derived from free radical oxidation of 7-DHC, many of which are yet to be fully characterised [92]. LC–MS3 spectra from SLOS plasma 
identifying (C) 26H,7− OC (upper panel) and 3βH,7O-CA (lower panel). Spectra of authentic standards can be found in [93]. (D) Levels of Gli1 mRNA (y-axis, mean 
arbitrary units ± SD, n = 3) were used as a metric for Hh signalling activity in NIH/3T3 cells after stimulation (7.5 h) with oxysterol (10 μM). With the exception of 
3β,7β-diHCA the oxysterol agonists induced Gli1 mRNA at 1 μM. (E) Immunoblots showing the amount of zSmo CRD captured on 20S− HC beads in the presence of 
the indicated competitors. 
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Fig. 5. Relative proportions (mole %) of bile 
acids with 7-oxo or 7β-hydroxy group conju-
gated with GlcNAc in urine from 3 SLOS pa-
tients and 6 controls determined by LC–MS. The 
SLOS patients were from the group who 
donated plasma. See Supplemental Figure S4 
for relevant chromatograms. Total bile acids 
include mono-, di- and tri-hydroxylated chol-
anoic acids and their single and doubly unsat-
urated equivalents singly, doubly or triply 
conjugated with glycine or taurine, sulfuric acid 
and GlcNAc. Mann-Whitney test was used for 
comparison of non-normally distributed data. *, 
P < 0.05; **, P < 0.01.   
Fig. 6. Oxysterols bind to Smo and modulate Hh signalling across the cell membrane. (A) Cartoon representation of Smo (CRD in silver, LD in red, TMD including 
ECL3 in blue. (B) Molecular modeling analysis of human Smo with cholesterol bound to the CRD, based on the crystal structure in [52]. (C) Schematic representation 
of the Hh signalling pathway showing 7-oxosterols activating Smo. 
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may be an explanation for this deficiency and consequently of malfor-
mations seen in SLOS. 
2.5. Molecular docking 
Recently, Byrne et al. solved the crystal structure of the human Smo 
protein consisting of the CRD (silver in Figs. 6 & 7 ), linker domain (LD, 
red) and the entire transmembrane domain (TMD, blue) but lacking its 
cytoplasmic tail, and unexpectedly found a cholesterol molecule bound 
to the CRD [52]. They concluded that Smo adopts an extended confor-
mation, with the extracellular CRD perched on top of the LD, which 
forms a wedge between the TMD and CRD. At the top of the wedge the 
CRD contacts the TMD through extracellular loop 3 (ECL3) of the TMD 
(Fig. 6). To investigate how the 7-oxo compounds which modulate Hh 
signalling and are found in SLOS plasma and in amniotic fluid, interact 
with Smo we carried out computational ligand docking [53] of these and 
other sterols to the human Smo CRD. The results show accurate docking 
of cholesterol (Fig. 7A) in the same location and almost identical 
orientation in the CRD groove as in the cholesterol-bound crystal 
structure [52], with good affinity, with the 3β-hydroxy group and sterol 
rings interacting with Asp95 (D95) and Pro107 (P107), respectively, of 
the CRD domain, with the sterol side-chain pointing downwards towards 
Leu491 (L491) of the helical region of ECL3 and Val210 (V210) of the LD 
region. The docking of 26H,7O-C (Fig. 7B) is almost identical to that of 
cholesterol. The compound occupies the same pocket in almost the same 
orientation with only sub-Ångstrom differences. The predicted binding 
affinity is slightly lower than for cholesterol (0.689 kcal/mol). Notably, 
Luchetti et al. have shown that, like 26H,7O-C, cholesterol activates the 
Hh signalling pathway by binding to the extracellular CRD of Smo [54]. 
25H,7O-C binds to the CRD with a notably different orientation, with the 
3β-hydroxy group and sterol rings pointing downwards towards the 
helical region of ECL3 and the side-chain, including 25-hydroxy group, 
pointing upward (Fig. 7C). Binding affinity is calculated to be 0.936 and 
0.247 kcal/mol weaker than for cholesterol and 26H,7O-C, respectively, 
but is still reasonably strong. There is no projection towards the ECL3 or 
LD regions. 3βH,7O-CA binds with comparable affinity to cholesterol, in 
the same pocket, and with a similar broad orientation, with good LD 
region proximity (V210) via the side-chain but slightly closer to the 
helical region of ECL3 (L491) than cholesterol, but with the 3β-hydroxy 
group and sterol rings further away from D95 and P107, respectively 
(Fig. 7D). The H-bond of the 3β-hydroxy group to D95 found in 26H, 
7− OC and cholesterol is lost in the 3βH,7O-CA bound structure. 7β, 
25-diHC, 7β,26-diHC, and 3β,7β-diHCA bind more deeply in the pocket 
(Fig. 7E-G), in similar orientation to 3βH,7O-CA, with side-chain prox-
imity to the LD region at V210 and to the helical region of ECL3 (L491), 
but with greater affinity than 3βH,7O-CA and similar affinity to 
cholesterol. Indeed, the calculated binding affinities of 7β,25-diHC and 
3β,7β-diHCA are marginally stronger than for cholesterol by 0.134 and 
0.218 kcal/mol, respectively. Interestingly, 3β,7β-diHCA, with the 
greatest affinity, sits deepest in the pocket. In agreement with a previ-
ously reported docking [35], 20S− HC binds to the same groove as 
cholesterol but in the opposite orientation (Fig. 7H, cf. H to A), with the 
sterol side-chain pointing towards D95. Despite this both cholesterol and 
20S− HC activate Hh signalling via the same CRD pocket [54]. 
3. Discussion 
Bile acid biosynthesis normally starts from cholesterol, however, 
CYP7A1 can also use 7-DHC as a substrate giving 7− OC as a product 
[38] which can be reduced by HSD11B1 to 7β− HC [39–41] opening a 
new route to bile acid biosynthesis, starting from 7-DHC and avoiding 
cholesterol (Fig. 1). The elevated levels of these two oxysterols in plasma 
of SLOS patients [44] and also those of 3β,7β-diHCA and 3β, 
7β-diH-Δ5-BA define a new and unexpected pathway for bile acid 
biosynthesis in SLOS patients (Figs. 1–3). Further evidence for this 
pathway is provided by the presumptive identification of 3β,7β, 
24-triHCA, a necessary intermediate as the CoA thioester in peroxisomal 
side-chain shortening of 3β,7β-diHCA to 3β,7β-diH-Δ5-BA (Fig. 1). 
Although the identification of 3β,7β,24-triHCA, and that of 3β,7β, 
25-triHCA, was made in the absence of authentic standards, the avail-
ability of standards for the 7α-epimers allowed the confident identifi-
cation of 7β-epimers based on accurate mass, expected retention times 
and MS3 spectra (Supplemental Figure S2I - N). A second branch of the 
pathway is initiated by CYP27A1 mediated (25R)26-hydroxylation of 
7− OC [55] and defined by the identification of 26H,7O-C, 3βH,7O-CA 
and 3βH,7O-Δ5-BA in SLOS plasma from patients with a high 7-DHC plus 
8-DHC to cholesterol ratio. Each 7-oxo compound presumably acts as a 
substrate for HSD11B1 and can be reduced to the 7β-hydroxy analogue 
[56]. A third branch to the pathway may proceed through 25H,7O-C, 7β, 
25-diHC and 3β,7β,25-triHCA, although it is not known whether 
CYP27A1 is responsible for the oxidation of the terminal carbon to the 
carboxylic acid and how the resulting acidic triol undergoes side-chain 
shortening (Fig. 1). The initiating enzyme of this third branch is not 
known as numerous CYP enzymes have 25-hydroxylase activity, as does 
CH25H [57]. Odermatt and colleagues have shown that both 25H,7O-C 
and 26H,7O-C can be reduced to their 7β-hydroxy analogues by 
HSD11B1, while the reverse reaction can be catalysed by HSD11B2 [56, 
58], and we speculate that 7-oxo and 7β-hydroxy acids may be similarly 
interconverted by these two enzymes (Fig. 1). 
As SLOS is a developmental disorder [37,59], we hypothesised that 
the unusual bile acid biosynthesis pathway may be active in the foetus 
and responsible for some of the phenotypical features of the disorder. To 
test the first part of this hypothesis we analysed amniotic fluid from 
SLOS affected pregnancies where both parents were carriers of SLOS 
(heterozygous with respect to mutations in DHCR7). As reported pre-
viously [47], 7-DHC plus 8-DHC was elevated in SLOS affected preg-
nancies and, as is detailed here, so are the ultimate unconjugated bile 
acids, 3β,7β-diH-Δ5-BA and 3βH,7O-Δ5-BA, in the pathway depicted in 
Fig. 1. The first enzyme in this pathway, required to convert 7-DHC to 
7− OC, is microsomal CYP7A1, this is expressed in adult liver [3], but in 
the infant is normally of only minor importance in bile acid synthesis 
[60]. However, microsomal 7α-hydroxylase activity is found in foetal 
liver [61,62] and CYP7A1 is evident in foetal heart and testis [63]. 
Mitochondrial CYP27A1 activity has been found in foetal liver [64], 
providing a route for (25R)26-hydroxylation and carboxylation of 7− OC 
[55,65], and also presumably of 7β− HC. HSD11B1, the enzyme required 
to reduce 7-oxosterols to their 7β-hydroxy analogues, is highly expressed 
in placenta, as is HSD11B2, the enzyme that catalyses the reverse re-
action [63,66]. This suggests a route to the 7β-hydroxy branch of the 
unusual pathway and cross over between different branches of the 
pathway via placenta and umbilical cord blood. The fact that others 
have found primary C24 bile acids in foetal gall bladder bile confirms 
that the foetus possesses the enzymatic machinery for side-chain 
shortening of C27 precursors to C24 acids [67,68], indicating that the 
necessary enzymes are present in the foetus to generate both 3β, 
7β-diH-Δ5-BA and 3βH,7O-Δ5-BA (Fig. 1). 
The 7β-hydroxy group in bile acids is known to become conjugated 
with GlcNAc, leading to the excretion of GlcNAc conjugates in urine 
[49]. Screening for bile acids in urine of SLOS patients to confirm the 
validity of the unusual pathway revealed statistically significant 
elevated levels of 3β,7β-diH-Δ5-BA conjugated with GlcNAc at the 7β 
position and also the double conjugate with glycine or taurine or with 
sulfuric acid, and the triple conjugate with GlcNAc, sulfuric acid and 
glycine or taurine (Fig. 5). The levels of these GlcNAc conjugates in SLOS 
urine do not overlap with levels of the corresponding compounds in 
control urine. 
Although in this study we have made no attempt to correlate SLOS 
severity with 7-oxo, 7β-hydroxy or 7β-GlcNAc metabolite levels the 
possibility exists that some of these metabolites may be of diagnostic or 
prognostic value. Furthermore, the identification of GlcNAc or sulfuric 
acid conjugates in maternal urine could have value in prenatal screening 
programmes, although these metabolites are also identified in NP-C 
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Fig. 7. Computationally docked structures of (A) cholesterol; (B) 26H,7O-C; (C) 25H,7O-C, (D) 3βH,7O-CA; (E) 7β,25-diHC; (F) 7β,26-diHC; (G) 3β,7β-diHC; and (H) 
20S− HC bound to the CRD of human Smo. In silico protein-ligand docking studies were performed using a combination of empirical and force-field approaches 
incorporated within an in-house pipeline called “Shipyard”, to predict the conformation and affinity of binding. 3β-hydroxy; 7β-hydroxy or 7-oxo; and side-chain 
hydroxy or carboxylic acids; are indicated by black; purple; and green; arrows respectively. 
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patients [29,31,32]. 
The data presented above is supported by a study performed on SLOS 
urine by Natowicz and Evans in 1994 using fast atom bombardment MS 
[69]. Although in the absence of chromatography or MS2 they were 
unable to fully characterise the metabolites, they were able to identify 
hydroxyoxocholenoic (H,O-Δ-BA) and dihydroxycholenoic (diH-Δ-BA) 
acids, their sulfuric acid conjugates and also a dihydroxycholenoic acid 
doubly conjugated with sulfuric acid and an aminohexose sugar [69]. 
Based on our studies these bile acid structures are appropriate to 3βH, 
7O-Δ5-BA and 3β,7β-diH-Δ5-BA and their conjugates with sulfuric acid 
and GlcNAc. 
Others have also studied bile acids in relation to SLOS [70,71]. Using 
a rat model for SLOS Honda et al. identified unusual Δ5,7 and Δ5,8 
3β-hydroxycholestadienoic acids from rat liver mitochondrial prepara-
tions, along with their precursors 26-hydroxy-7-dehydrocholesterol and 
26-hydroxy-8-dehydrocholesterol [70]. The identification of the latter 
metabolite in SLOS plasma was confirmed in a subsequent report [44]. 
Unlike in the present study, Honda et al. did not profile for 7-oxo or 
7β-hydroxy acids. Steiner et al. have analysed free bile acids from stool 
of SLOS patients and controls after cleavage of conjugates but did not 
structurally identify the unusual bile acids present in the samples [71]. 
Shoda et al. have suggested that enzymatic mitochondrial oxidor-
eduction of 7α-hydroxy-5-ene sterols to their 7β-hydroxy epimers can 
occur in liver [72]. In fact, they found that human liver mitochondria 
rapidly convert 7α,26-diHC and 3β,7α-diHCA to their corresponding 
7β-hydroxy epimers in an isocitrate dependent manner, perhaps through 
their 7-oxo intermediates, providing an alternative route to 3β, 
7β-diH-Δ5-BA [72]. Additionally, 7α-hydroxy epimerisation may be 
catalysed by the intestinal flora during the enterohepatic circulation to 
produce ursodeoxycholic and ursocholic acids present in bile and urine 
of healthy humans [49,73]. It is likely, that there are several pathways to 
7β-hydroxy bile acids in human of varying importance in health and 
disease. 
It is noteworthy that previous studies have identified 3β,7β-diH-Δ5- 
BA singly conjugated with GlcNAc at the C-7β position, doubly conju-
gated with GlcNAc and sulfuric acid at C-7β and C-3β, respectively, and 
triply conjugated with GlcNAc, sulfuric acid and glycine or taurine at C- 
7β, C-3β and C-24, respectively, in urine of patients suffering from NP-C 
disease [29,31,32]. NP-C is a rare inherited lipid trafficking disorder 
which amongst other symptoms presents with learning difficulties and 
progressive intellectual decline, behaving as a neurodegenerative dis-
order. In contrast, SLOS causes microcephaly and developmental delay. 
Children with NP-C do not show the classic dysmorphic features seen in 
SLOS. In one of the early studies on NP-C, 3βH,7O-Δ5-BA was identified 
as the 3β-sulfate and also conjugated with glycine or taurine and it was 
suggested that 3βH,7O-Δ5-BA was an intermediate in the biosynthesis of 
the 3β,7β-diH-Δ5-BA 7β-GlcNAc conjugates [29]. In a latter study both 
3β,7β-diH-Δ5-BA and 3βH,7O-Δ5-BA were identified in NP-C and NP-B 
plasma [30]. Recent studies by Maekawa et al. suggested 3β, 
7β-diH-Δ5-BA conjugated with sulfuric acid at C-3β and GlcNAc at C-7β 
as a urinary biomarker for NP-C disease [32]. However, Clayton and 
colleagues have found that some NP-C patients carry the cT361G mu-
tation in UGT3A1 leading to the amino acid substitution p.C121G and an 
absence of activity of the encoded 7β-hydroxy bile acid UDP N-acetyl-
glucosaminyl transferase [31]. As 20 % of the Asian and Caucasian 
populations are homozygous for this mutation, it can be expected that 
20 % of NP-C and also of SLOS patients will not show GlcNAc conjugates 
in urine. In the absence of functional 7β-hydroxy bile acid UDP N-ace-
tylglucosaminyl transferase it can be expected that sulfuric acid conju-
gates of 7β-hydroxy- and 7-oxo-Δ5-bile acids would be further elevated 
in urine. In our small study of urine samples, all SLOS patients excreted 
GlcNAc conjugates, so this hypothesis was not tested. In the original 
publication by Alvelius et al. it was suggested that the 7-oxo- and 
7β-hydroxy bile acids observed may be a consequence of extensive lipid 
peroxidation of cholesterol in NP-C disease [29]. This seems likely to be 
correct as elevated levels of 7− OC and also cholestane-3β,5α,6β-triol, 
derived enzymatically from 5,6-epoxycholesterol, like 7− OC a peroxi-
dation products of cholesterol, are found in plasma of NP-C patients [30, 
31]. Importantly, cholestane-3β,5α,6β-triol is not elevated in plasma of 
SLOS patients indicating that different oxidative mechanisms are at play 
in SLOS and NP-C. Additionally, the absence or presence of elevated 
levels cholestane-3β,5α,6β-triol or its further metabolites in plasma al-
lows the simple biochemical differentiation of SLOS from NP-C. The 
presence of elevated concentrations of 7− OC in NP-C plasma, in this 
case generated through peroxidation mechanisms, should also lead to a 
pattern of bile acid precursors similar to those presented in Fig. 1. This is 
in fact the case and supports the bile acid biosynthesis pathway pre-
sented in Fig. 1 [30]. 
The SLOS phenotype is very broad; severely affected cases often die 
in utero or soon after birth, whereas mild cases show only minor physical 
abnormalities and learning and behavioural problems [37]. Limb ab-
normalities are common in SLOS and, in addition to physical malfor-
mations, SLOS patients have impaired cognitive function although 
normal intelligence is also possible [37]. Some SLOS patients present 
with cholestatic liver disease, as do some patients with the bile acid 
synthetic defect CTX and larger numbers of patients with NP-C disease, 
perhaps due to a lack of primary bile acid dependent bile flow, as in the 
primary defects of bile acid biosynthesis, but this could also be due to 
potential toxicity of abnormal bile acids. Although the primary enzy-
matic defect in SLOS is well defined, its pathophysiology is not, and it is 
unlikely that only one mechanism explains the myriad of symptoms. It is 
tempting to speculate that some of the metabolites of the newly defined 
bile acid biosynthesis pathway (Fig. 1) explain some of SLOS phenotypic 
features. In fact, 3β,7β-diHCA is toxic towards neurons and may be 
responsible for some of the neurological symptoms of the disease [25]. 
Hh signalling is required for embryonic patterning and regeneration 
of postembryonic tissue and aberrant Hh signalling has been linked to 
SLOS [33,37,74–76]. In fact, many developmental malformations 
attributed to SLOS occur in tissues where Hh signalling is required for 
development [75]. DHCR7, the defective enzyme in SLOS, has been 
implicated to function as a positive regulator of Hh signalling, while the 
cause of some of the developmental abnormalities seen in SLOS have 
been attributed to cholesterol deficiency interfering with normal Hh 
signalling [74,76]. Alternatively, Koide et al. have suggested that 
DHCR7 functions as a negative regulator of Hh signalling and its 
inhibitory affect is at the level, or downstream, of the oncoprotein Smo 
[75]. Both of these proposals can be accommodated by a model sug-
gested by Beachy and colleagues where oxysterols and cholesterol could 
bind to and modulate Smo at different structural regions [33,77]. Smo is 
a seven-transmembrane protein with extended extracellular and cyto-
plasmic termini. Hh pathway activation is initiated by binding of 
cholesterol-modified SHH protein to its receptor Ptch1, an antiporter 
protein, which releases inhibition of Smo and triggers transcription of 
Hh target genes via the Gli family of transcription factors (Fig. 6) [36,78, 
79]. It has been shown that the extracellular CRD is the site for oxysterol 
binding to Smo and suggested that oxysterols may stabilise an active 
Smo conformation [33,51,80]. Recently, Byrne et al. determined the 
crystal structure of Smo and found a cholesterol molecule bound to the 
CRD [52]. They proposed that cholesterol functions as an endogenous 
Smo ligand that occupies the CRD groove and there is now compelling 
evidence that cholesterol is sufficient to activate Hh signalling through 
the CRD site [54,81,82]. Interestingly, Deshpande et al. have shown that 
when stabilised in an active state, SMO has two sterol binding sites, one 
in its CRD and a second in the transmembrane domain [77], however, 
most evidence to date indicates that activating oxysterols bind to the 
CRD. With respect to Hh signalling, 20S− HC has been regarded as an 
archetypal oxysterol and has been shown to be a potent activator of Smo 
in vitro [51] but has been difficult to detect in vivo, questioning it 
physiological relevance [20,83,84]. However, recent studies have 
confirmed the earlier identification of 20S− HC in brain and in placenta 
[20,84]. It is difficult to compare the activation capacity of cholesterol 
with oxysterols, as while synthetic oxysterols can be added to cells, all 
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cellular systems will be rich in endogenous cholesterol making effects 
due to addition of exogenous cholesterol difficult to assess [82]. Such 
comparisons are further complicated by the insolubility of cholesterol in 
cell media. Perhaps with the recent introduction of quantitative mass 
spectrometry imaging technology [20,85], relative levels of endogenous 
oxysterols and cholesterol can be measured in developing tissue e.g. 
developing vertebrate spinal cord. 
In the current study, we identify 25H,7O-C and 26H,7O-C in SLOS 
plasma and confirm them, as reported earlier [33], as activators of Smo 
even in the absence of SHH (Fig. 4D). 26H,7O-C has been shown pre-
viously to be generated from 7− OC in HepG2 cells by CYP27A1 [55] 
(Fig. 1) and has also been identified in extracts of retinal pigment 
epithelial cells [65]. The enzyme involved in 25-hydroxylation of 7− OC 
to 25H,7− OC is less clear cut as multiple CYPs, and also CH25H, have 
25-hydroxylase activity [3,4,57]. As 7− OC is derived from 7-DHC by 
CYP7A1 oxidation, the identification in the current study of SMO ago-
nists 25H,7O-C in SLOS plasma and of 26H,7O-C in SLOS plasma and in 
amniotic fluid from SLOS affected pregnancies lends weight to the hy-
pothesis of Koide et al. that DHCR7, which reduces the pool of 7-DHC 
substrate by metabolism to cholesterol (Fig. 1), functions as a negative 
regulator of Hh signalling at the level of Smo [75]. Although 25H,7O-C 
and 26H,7O-C are absent, or present at only very low levels, in control 
plasma and amniotic fluid samples the presence of down-stream me-
tabolites in plasma and amniotic fluid from healthy individuals and 
pregnancies indicates that the pathway involving their formation is 
active in human. Like 26H,7O-C, 3βH,7O-CA has been identified in 
retinal pigment epithelial cells and is derived by CYP27A1 oxidation of 
7− OC [65]. This acid which is present in SLOS plasma and amniotic 
fluid from affected pregnancies and to a minor extent in control samples, 
is structurally similar to 26H,7O-C and, as shown here, also activates Hh 
signalling (Fig. 4). The involvement of three 7-oxo metabolites of 7-DHC 
(i.e. 25H,7O-C, 26H,7O-C and 3βH,7O-CA) in Hh signalling can explain 
conflicting results suggesting DHCR7 is both a positive [74] and nega-
tive [75] regulator if one assumes that these 7-oxosterols have differing 
degrees of activity towards SMO and may act as partial agonists 
providing positive regulation, or competing against full agonists 
resulting in negative regulation. Although not detected in amniotic 
fluid, we show here that 7β,26-diHC and 7β,25-diHC both activate the 
Hh signalling pathway (Fig. 4D). This confirms the data of Raleigh et al. 
who also found that 7β,26-diHC activates the Hh signalling pathway via 
the CRD domain of SMO [34]. 
Our data from computational molecular docking of the 7-oxo and 7β- 
hydroxy compounds to the CRD of human Smo indicate binding to the 
same groove as cholesterol and 20S− HC but with each 7-oxidised me-
tabolites in a somewhat different orientation (Fig. 7). The docking of 
26H,7O-C is almost identical to that of cholesterol (Fig. 7A & B), but that 
of 25H,7O-C (Fig. 7C) is notably different with the 3β-hydroxy group 
and sterol rings pointing downwards towards the helical region of the 
ECL3 (blue in Fig. 7), rather than associating with the D95 loop and 
alpha helices of CRD (silver in Fig. 7), as is the situation with cholesterol 
and 26H,7O-C (Fig. 7A & B). The 25H,7O-C docking shows the sterol 
side-chain and 25-hydroxy group pointing upward and proximal to the 
P107 loop region (Fig. 7C). 3βH,7O-CA (Fig. 7D), binds more strongly to 
Smo than the agonists 26H,7O-C, 25H,7O-C or 20S− HC, in a similar 
orientation to 26H,7O-C but proximity to D95 towards the top of the 
binding groove is lost. 7β,25-diHC, 7β,26-diHC and 3β,7β-diHCA 
(Figure E–G) bind more deeply in the pocket, in similar orientation to 
3βH,7O-CA with side-chain proximity to the LD region at V210 (red in 
Fig. 7) and to the helical region of ECL3 (L491), but with greater affinity 
than 3βH,7O-CA and similar affinity to cholesterol. Byrne et al. sug-
gested that CRD agonists may induce a conformational change in Smo 
involving a shift of the ECL3 and pivoting of the CRD on the end of the 
TMD to provide signal transduction across the membrane. 
The balance between accessible cholesterol, oxysterol agonists and of 
3β,5α-dihydroxycholest-7-en-6-one, also derived from 7-DHC and 
recently shown to inhibit Hh signalling [86], may explain the broad 
spectrum of the SLOS phenotype. Interestingly, 3β,5α-dihydrox-
ycholest-7-en-6-one, which we previously found in SLOS plasma at 
about the same level as reported here for 26H,7O-C [44], inhibits the 
agonistic effect of 26H,7O-C on Hh signalling (25 μM 3β,5α-dihydrox-
ycholest-7-en-6-one inhibited the effect of 10 μM 26H,7O-C in a 
Gli-luciferase assay by about 80 %) in a non-competitive manner, pre-
sumably through binding at a site on SMO distinct from the binding 
pocket populated by 26H,7O-C [86]. The concept of accessible choles-
terol as a determinant of Hh signalling, as recently evoked by Kinnebrew 
et al. [82], defines only a small fraction of membrane cholesterol as 
accessible for Smo activation. It is not unreasonable to expect this pool 
of cholesterol to be reduced in SLOS, enhancing the importance of the 
balance between multiple competing oxysterol agonists of differing ef-
ficacy in determining the ultimate SLOS phenotype. Besides SLOS, other 
disorders of cholesterol biosynthesis and metabolism present with 
developmental malformations in tissues where embryonic patterning 
depends on Hh signalling [37]. Like SLOS these may also result from an 
imbalance of SMO agonists. Unlike, disorders of cholesterol biosyn-
thesis, NP-C does not show dysmorphic features characteristic of SLOS 
nor do NP-C children show developmental delay. This suggests that the 
Hh signalling pathway is not disturbed in the NP-C foetus, presumably as 
the non-enzymatic formation of 7− OC, the initiating step in the 
7-oxo/7β pathway in this disorder, is less prevalent in the foetus where 
partial pressure of oxygen is lower than after parturition. Further study 
will be required to test this hypothesis. 
In summary, we have identified an unusual pathway of bile acid 
biosynthesis starting from 7-DHC, rather than cholesterol, which is 
evident in SLOS patients. The pathway is also active in healthy controls 
to a minor extent. The relative importance of pathway intermediates on 
Hh signalling may be revealed in future studies utilising sterol-specific 
mass spectrometry imaging in tissues where Hh signalling is required 
for development [20,85]. 
4. Experimental procedures 
4.1. Materials 
Sources of materials for LC–MS(MSn) analysis and of authentic 
standard compounds can be found in [32,42–44,49]. 
4.2. Human samples 
All participants or their parents/guardians provided informed con-
sent and the study was performed with institutional review board 
approval (REC08/H1010/63) and adhered to the principles of the 
Declaration of Helsinki. Historical and newly collected SLOS plasma 
samples (n = 10 patients) were as described in [44]. SLOS urine samples 
(n = 3 patients) were from Central Manchester University Hospitals 
NHS Foundation Trust. The urine samples were form the group of pa-
tients who donated plasma. SLOS samples were received with limited 
clinical data i.e. sex, diagnosis. Deidentified amniotic fluid samples 
(SLOS affected pregnancies n = 5, healthy pregnancies n = 12) were 
from Kennedy Krieger Biochemical Genetics Laboratory, Baltimore, USA 
as reported in [47]. Control plasma samples (n = 24) were from a pre-
viously reported study [43]. Control urine samples (n = 6 volunteers) 
were kindly provided by the Joint Clinical Research Facility, Swansea 
University / ABMU Local Health Board. 
4.3. Extraction and analysis of sterols and oxysterols from plasma and 
amniotic fluid 
Sterols and oxysterols were extracted from plasma as described in 
[42–44]. The extraction procedure was essentially the same for amniotic 
fluid with minor modifications. We utilised a charge-tagging protocol to 
maximise sensitivity for LC–MS(MSn) analysis (Supplemental Figure S1). 
Full details are provided in Supplemental Experimental Procedures. 
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4.4. Extraction and analysis of bile acids from urine 
Working solutions of [2,2,4,4-2H4]cholic acid (20 ng/μL), 
[2,2,4,4-2H4]glycochenodeoxycholic acid (20 ng/μL) and [2,2,4,4-2H4] 
taurochenodeoxycholic (20 ng/μL) were prepared in absolute ethanol. 
2 μL (40 ng) of each working solution was added to 994 μL of water in a 
2 mL microcentrifuge tube. Urine (100 μL, pH 6–7) was added drop-wise 
to the 1 mL of water containing deuterated standards. After 10 min 
ultrasonication the solution was centrifuged at 17,000 g, 4 ◦C for 30 min 
and the supernatant retained. An Oasis HLB (60 mg, Waters, Elstree, UK) 
column was washed with absolute ethanol (4 mL), methanol (4 mL) and 
conditioned with water (4 mL). The supernatant from above was loaded 
onto the column and allowed to flow at 0.25 mL/min. After a 3 mL wash 
with water, bile acids were eluted in 4 × 1 mL of methanol. The first two 
1 mL fractions (containing bile acids) were combined, diluted to 60 % 
methanol and analysed by LC–MS(MSn) in an identical fashion to deri-
vatised oxysterols [42] with the exception that bile acid urine analysis 
was performed in the negative ion mode. 
4.5. Statistics 
A Mann-Whitney test was used for non-normally distributed data. A 
P value of 0.05 or less was considered statistically significant. 
4.6. Hedgehog signaling assays using quantitative RT-PCR 
Gli1 mRNA, encoded by a direct Hh target gene, was measured by 
quantitative real-time reverse-transcription PCR as described in [54] 
with minor modifications (see Supplemental Experimental Procedures). 
4.7. Oxysterol ligand affinity chromatography 
Purified zSmo ectodomain protein (zebrafish Smo CRD expressed in 
HEK-293 T cells) was diluted in 20 mM Tris pH 8.5, 150 mM NaCl, 0.3 % 
octyl-glucoside prior to addition of competitors (100 μM) and 20S− HC 
beads (1:200) [35]. Binding was allowed to proceed for 12 h at 4 ◦C, and 
then the resin was washed and captured protein eluted with four washes 
with sodium dodecyl sulfate (SDS) with 100 μM dithiothreitol (DTT). 
The zSmo ectodomain was measured by colloidal Coomassie staining 
[35]. 
4.8. Molecular docking 
In silico protein-ligand docking studies were performed using a 
combination of empirical and force-field approaches incorporated 
within an in-house pipeline called “Shipyard”, to predict the confor-
mation and affinity of binding. The crystal structure of the human Smo 
protein was obtained from the RCSB Protein Data Bank (PBD, 5L7D) in 
complex with cholesterol [52]. A mapping of all pockets and grooves of 
the Smo protein structure was generated using Sphgen [87]. The binding 
pockets were confirmed using DoGSiteScorer [88]. Output of the bind-
ing site search was verified manually via comparison with the original 
crystal structure. All ligand structures were subjected to the Open Babel 
system to make hydrogen atoms explicit [89]. 
To generate the 10 best poses for ligands in the Smo protein, docking 
was performed using DOCK 6 [87] and AutoDock Vina [53], which 
assign a binding energy score and rank. The pool of possible confor-
mations was independently rescored using the DOCK 6 force field, the 
AutoDock Vina empirical scoring method, and the DSX (DrugScore 
eXtended) knowledge-based statistical potential [90]. An overall best 
pose was selected from the pool according to a consensus-by-rank 
scheme across the three scores. The AutoDock Vina score of the cho-
sen conformation was taken as the prediction of the binding affinity of 
the ligand. Images of best poses of selected candidates were generated in 
Chimera [91]. 
Footnote 
The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of 
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